Last reviewed · How we verify
The Efficacy And Safety Of Metformin For The Treatment Of Atrial Fibrillation (MAFT)
The aim of this multicenter, pragmatic, open-label, randomized, placebo-controlled clinical trial is to test whether repurposing metformin for the treatment of atrial fibrillation will be effective in decreasing patients' hospitalization, adverse major cardiovascular events, and non-cancer death. Participants will be randomized into 2 study arms (385 participant each), whereby: * The Metformin Group (MG): will receive metformin oral tablets in addition to the standard rate/rhythm control strategy and anticoagulation. * The Placebo Control Group (PCG): will receive placebo oral tablets as a control group in addition to the standard rate/rhythm control strategy and anticoagulation. Then both arms will be compared according to the these endpoints: * The primary endpoint is hospitalization due to an episodic AF or an AF with a rapid or slow ventricular response (in the case of permanent AF). * The secondary endpoint is a composite of non-fatal major cardiovascular adverse events or non-cancer death. The non-fatal major cardiovascular adverse events include: * Hospitalization due to heart failure. * Non-fatal myocardial infarction. * Non-fatal stroke. * Hospitalization due to unstable angina.
Details
| Lead sponsor | Arab Contractors Medical Centre |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 770 |
| Start date | 2024-06-01 |
| Completion | 2025-04 |
Conditions
- Atrial Fibrillation
Interventions
- Metformin
- Placebo
Primary outcomes
- Primary Endpoint — 12 months since randomization
The primary endpoint is hospitalization due to an episodic AF or an AF with a rapid or slow ventricular response (in the case of permanent AF).
Countries
Egypt